Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ddg.13037_g | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Enfortumab vedotin and pembrolizumab : Management of side effects during first line combined treatment for advanced or metastatic urothelial carcinoma].
Urologie
January 2025
Medizinische Klinik VI, Nationales Zentrum für Tumorerkrankungen (NCT), Universitätsklinikum Heidelberg, Heidelberg, Deutschland.
The aim of this article is to raise awareness among healthcare providers about the adverse events (AEs) associated with the combined treatment with enfortumab vedotin and pembrolizumab. The differential diagnostic allocation of these AEs to the respective agents is discussed, overlaps between the side effect profiles of the two drugs are identified and strategies for an effective management of these AEs are presented. The recommendations are based on the currently valid prescription information for both drugs, the results of pivotal approval studies and the guidelines of recognized specialist organizations as well as the clinical experience of the authors.
View Article and Find Full Text PDF[Adjuvant therapy for renal cell carcinoma : Relevant patient and tumor factors].
Urologie
December 2024
Klinik für Innere Medizin (Tumorforschung) und Klinik für Urologie, Westdeutsches Tumorzentrum Essen, Universitätsklinikum Essen, Essen, Deutschland.
The gold standard in the treatment of localized and locally advanced renal cell carcinoma is surgery. Nevertheless, there is still a risk of tumor relapse. Reducing the risk of recurrence and extending overall survival is the goal of subsequent adjuvant treatment.
View Article and Find Full Text PDF[Induction of Uveitis by Immune-Oncologic Therapies, Namely Checkpoint Inhibitors].
Klin Monbl Augenheilkd
April 2022
Berner Augenklinik am Lindenhofspital, Swiss Eye Institute, Universität Bern, Bern, Schweiz.
Background: The recently introduced tumor therapies including immune checkpoint and BRAF/MEK inhibitors (ICI) have substantially contributed to survival and quality of life of the affected patients, but are associated with class-specific, non-toxic immune-related side effects including uveitis. This narrative review focusses to summarize the immune-related adverse event profile associated with the use of ICI.
Methods: A literature search in PubMed, the publication database of the National Institute of Health in the USA (https://www.
[Immunotherapy in urologic oncology : Response and treatment interruptions due to adverse events in a bicentric real-world analysis].
Urologie
July 2022
Klinik für Urologie und Urochirurgie, Universitätsklinikum Mannheim, Medizinische Fakultät Mannheim, Universität Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Deutschland.
Background: Immune checkpoint inhibitors (ICI) have been approved in uro-oncology for a few years. Real-world experience regarding benefits and risks with novel side effects are rare.
Materials And Methods: In a retrospective analysis, all patients who received ICI therapy due to metastatic renal cell carcinoma (NCC) or urothelial carcinoma (UCA) were enrolled at two maximum care hospitals in Germany between July 2016 and May 2021.
Translational Highlights in Breast and Ovarian Cancer 2019 - Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy.
Geburtshilfe Frauenheilkd
December 2019
Charité University Hospital, Campus Benjamin Franklin, Department of Hematology, Oncology and Tumour Immunology, Berlin, Germany.
In the near future, important translational questions of clinical relevance will be adressed by studies currently in progress. On the one hand, the role of PD-L1 expression must be further understood, after it was found to be relevant in the use of atezolizumab in first-line therapy of patients with metastatic triple-negative breast cancer (TNBC). No association between efficacy and PD-L1 expression was found in a neoadjuvant study that included pembrolizumab in TNBC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!